

PARK CITY, UTAH • MARCH 11-13, 2021



SUPPORT PROSPECTUS
2021 NASH-TAG CONFERENCE
THERAPEUTIC AGENTS FOR NON-ALCOHOLIC
STEATOHEPATITIS AND FIBROSIS

TABLE OF CONTENTS

3	Executive Summary
4	Course Directors/Scientific Advisory Board Committee
5	Agenda
8	2021 NASH-TAG Support Opportunities and Important Deadlines
9	2021 NASH-TAG Conference Sponsorship Opportunities
10	2021 NASH-TAG Exhibit/Sponsor Information Form
11	Exhibitor Registration Instructions



EXECUTIVE SUMMARY

We are pleased to announce that the 2021 NASH/TAG Conference, our fifth annual conference, will be a **hybrid** conference on Thursday, March 11-13, 2021 in Park City, UT. The new dates and new hybrid format will provide an effective, engaging and safe opportunity to learn from leading researchers, to engage in interactive discussions and to share insight with others on multiple topics related to advances in the diagnosis and management of patients with NASH/NAFLD and liver fibrosis.

The NASH-TAG conference's primary objective is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with NASH/NAFLD. The conference brings together clinicians, academia, and the pharmaceutical industry to discuss identification of the appropriate patient populations, trial designs, and therapeutic endpoints, as well as the potential benefits these agents can have on patients with NASH. We believe the success of this conference is accomplished by delivering a focused scientific educational update that highlights the most clinically-relevant advances in NASH, which include the future directions in diagnostic procedures and the challenges in drug discovery and development for both NASH and liver fibrosis.

The Scientific Advisory Council of NASH-TAG is an internationally renowned group of academic researchers who help in providing comprehensive strategic planning and guidance for the educational program. These renowned experts will assist in the development of the educational content and will serve as faculty at the conference. They will address the latest clinical trial results, design updates, new pharmacological updates, and the pharmacoeconomic benefit of future treatment to the healthcare system. In addition, the faculty will focus on epidemiology, comorbidities associated with this disease, and the impact of NASH/NAFLD (natural history).

THE CONFERENCE DIRECTORS AND FACULTY CONGRATULATES THE SELECTED 2020 NASH-TAG FUTURE LEADERS IN NASH:



Veeral Ajmera, MD, MAS

Assistant Professor of Medicine
Medical Director of Liver Transplantation
Division of Gastroenterology and Hepatology
University of California, San Diego
La Jolla, California



Alina M. Allen, MD

Gastroenterologist
Liver Transplant Program
Mayo Clinic
Boston, Massachusetts



Michelle T. Long, MD, MSc

Assistant Professor of Medicine
Boston University School of Medicine
Boston, Massachusetts



Eduardo Vilar-Gómez, MD, PhD

Assistant Research Professor of Medicine
Indiana University School of Medicine
Indianapolis, Indiana

2020 NASH-TAG CONFERENCE HIGHLIGHTS:


Over 255 attendees

Of those who responded to our post conference survey **over 88% were very satisfied with the conference**

Over 80% are definitely coming back to the 2021 conference

Over 95% of respondents would recommend this conference to others and **plan to attend the 2021 meeting**

2020 ATTENDEE DEMOGRAPHICS



COURSE DIRECTORS



Michael Charlton, MD, MBBS, FRCP
Professor of Medicine
Chief of Hepatology,
Director Transplant Institute
University of Chicago
Chicago, IL



Stephen Harrison, MD, FAASLD
Visiting Professor of Hepatology,
Radcliffe Department of Medicine,
University of Oxford
San Antonio, TX



Rohit Loomba, MD, MHSc
Professor of Medicine and Vice Chief,
Division of Gastroenterology
Adjunct Professor, Epidemiology and Public Health
University of California, San Diego
San Diego, CA



Vlad Ratziu, MD
Professor of Hepatology
Hôpital Pitié Salpêtrière, Institute of
Cardiometabolism and Nutrition and Université
Paris, France

SCIENTIFIC ADVISORY BOARD COMMITTEE

Manal Abdelmalek, MD
Duke University
Durham, NC

Quentin Anstee, MD
Newcastle University
Newcastle-Upon-Tyne,
United Kingdom

Stephen H. Caldwell, MD
University of Virginia
Charlottesville, VA

Kenneth Cusi, MD, FACP, FACE
University of Florida
Gainesville, FL

Anna-Mae Diehl, MD
Duke University
Durham, NC

Scott Friedman, MD
Mount Sinai Hospital
New York, NY

Samuel Klein, MD
Washington University
School of Medicine
St. Louis, MO

Yuri Popov, MD, PhD
Harvard Medical School
Boston, MA

Mary Rinella, MD
Northwestern University
Feinberg School of Medicine
Chicago, IL

Arun J. Sanyal, MD
Virginia Commonwealth University
Medical Center
Richmond, VA

Detlef Schuppan
Mainz University Medical Center
Mainz, Germany

Gerald I. Shulman, MD, PhD
Yale University School of Medicine
New Haven, CT

Bart Staels, PhD
University of Lille Nord de France
Lille, France

Frank Tacke, MD, PhD
University Hospital Aachen
Aachen, Germany

Brent A. Tetri, MD
Saint Louis University Liver Center
St. Louis, MO

Vincent Wong, MD
The Chinese University of Hong Kong
Hong Kong, China

Hannele Yki-Jarvinen, MD, PhD
University of Helsinki
Helsinki, Finland

Zobair Younossi, MD
Inova Health System
Falls Church, VA

For an updated list of faculty/speakers, please visit our website:

WWW.NASH-TAG.ORG

Conference management services provided by:

Focus Medical Communications

AGENDA

**** Mountain Standard Time ****

FRIDAY, MARCH 12, 2021

6:45 – 7:30 Breakfast – Exhibit Hall/Poster Viewing

7:30 – 8:00 **The Year 2020 in Review**
Presenter: Michael Charlton, MD, MBBS, FRCP
University of Chicago,
Chicago, Illinois, USA

SESSION 1: LATEST CLINICAL TRIAL RESULTS – 1. WITH HISTOLOGY DATA

Moderators: Mary Rinella, MD – Northwestern University Feinberg School of Medicine (Chicago, Illinois, USA), and
Rohit Loomba, MD – University of California at San Diego (San Diego, California, USA)

8:00 – 8:20 **Tropifexor**
Presenter: Arun Sanyal, MD
VCU Health
Richmond, Virginia, USA

Rebuttal: Vlad Ratziu, MD
Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris
Paris, France

8:20 – 8:30 Open Mic Discussion

8:30 – 8:50 **Lanifibranor**
Presenter: Manal Abdelmalek, MD, MPH
Duke University
Durham, North Carolina, USA

Rebuttal: Brent A. Tetri, MD
Saint Louis University School of Medicine
Saint Louis, Missouri, USA

8:50 – 9:00 Open Mic Discussion

9:00 – 9:20 **Semaglutide**
Presenter: Philip Newsome, MBBS
University of Birmingham
Birmingham, United Kingdom

Rebuttal: Mazen Nouredin, MD, MHSc
Cedars Sinai Medical Center
Los Angeles, California, USA

9:20 – 9:30 Open Mic Discussion

9:30 – 9:50 Break – Exhibit Hall/Poster Viewing

AGENDA

SESSION 2: LATEST CLINICAL TRIAL RESULTS – 2. EARLY PHASE 2A TRIALS

Moderators: Manu Chakravarthy, MD, PhD – Executive Vice President of Clinical Development – Chief Medical Officer – Axcella Health, Inc. (Cambridge, Massachusetts, USA), Adrian M. Di Bisceglie, MD – Chief Medical Officer – HighTide Therapeutics (Saint Louis, Missouri, USA), and Stephen Harrison, MD – University of Oxford (San Antonio, Texas, USA)

9:50 – 10:05

FGF-21 89 Bio

Presenter: Rohit Loomba, MD, MHSc
University of California at San Diego
San Diego, California, USA

10:05 – 10:25

Efruxifermin

Presenter: Stephen Harrison, MD
University of Oxford
San Antonio, Texas, USA

10:25 – 10:35

FASN Inhibitor Sagimet Trial

Presenter: Rohit Loomba, MD, MHSc
University of California at San Diego
San Diego, California, USA

10:35 – 10:40

Q&A

BEYOND SUCCESS STORIES, WHY DO SO MANY NASH TRIALS FAIL?

Moderators: Michael Charlton, MBBS, FRCP – University of Chicago (Chicago, Illinois, USA), and Brent A. Tetri, MD – Saint Louis University School of Medicine (Saint Louis, Missouri, USA)

10:40 – 11:20

Non-Cirrhotic

Presenter: Vlad Ratziu, MD
Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris
Paris, France

Cirrhotic

Presenter: Mary Rinella, MD
Northwestern University Feinberg School of Medicine
Chicago, Illinois, USA

11:20 – 12:00

Rapid Fire on Promising Data

Presenters: Michael Charlton, MBBS, FRCP
University of Chicago
Chicago, Illinois, USA

Rohit Loomba, MD, MHSc
University of California at San Diego
San Diego, California, USA

Naim Alkhouri, MD
Arizona Liver Health
Glendale, Arizona, USA

12:00 – 16:00

Interactive Dialogue on NASH Topics

SESSION 3: INNOVATIVE TRIAL DESIGN – PLATFORM TRIALS FOR NASH: FACT OR FANCY?

Moderators: Nicholas Di Prospero, MD, PhD – Senior Director, Clinical Development – Janssen Pharmaceuticals (Raritan, New Jersey, USA), Vlad Ratziu, MD – Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris (Paris, France), Manal Abdelmalek, MD, MPH – Duke University (Durham, North Carolina, USA), and Mary Rinella, MD – Northwestern University Feinberg School of Medicine (Chicago, Illinois, USA)

16:00 – 16:25

The Concept of Platform Trials

Presenter: Nicholas Di Prospero, MD, PhD
Senior Director, Clinical Development
Janssen Pharmaceuticals
Raritan, New Jersey, USA

AGENDA

- 16:25 – 16:50 **Specific Challenges and Opportunities for NASH Trials**
Presenter: Vlad Ratziu, MD
Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris
Paris, France
- 16:50 – 17:00 **Panel Discussion**
Panelists: Vlad Ratziu, MD
Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris
Paris, France

Nicholas Di Prospero, MD, PhD
Senior Director, Clinical Development
Janssen Pharmaceuticals
Raritan, New Jersey, USA

Kitty Yale
Chief Development Officer
Akerio Therapeutics
San Francisco, California, USA

Hsiao D. Lieu, MD, FACC
Chief Medical Officer and Senior Vice President
NGM Biopharmaceuticals
San Francisco, California, USA

Hank Mansbach, MD
Chief Medical Officer
89bio, Inc.
San Francisco, California, USA
- 17:00 – 17:15 **Seladelpar's FDA Hold and Release: What Happened and What Did We Learn?**
Presenter: Stephen Harrison, MD
University of Oxford
San Antonio, Texas, USA
- 17:15 – 17:35 **Break – Exhibit Hall/Poster Viewing**
- 17:35 – 17:55 **Automated Histological Analysis – Seeing Beyond the Pathologist's Eye**
Presenter: Quentin Anstee, BSc(Hons), MBBS, PhD
Newcastle University
Newcastle upon Tyne, United Kingdom
- 17:55 – 18:10 **What Does it Take for Automated Histological Analysis/Prime Time – What Does it Take to be Accepted – Are We There Yet?**
Presenter: Andrew H. Beck, MD, PhD
Co-Founder & Chief Executive Officer
PathAI
Boston, Massachusetts, USA
- 18:10 – 18:25 **Breaking Down Cirrhotic Lesions – Implications for Drug Development**
Presenter: Dean Tai, PhD
Co-Founder, Chief Scientific Officer
Histoindex
Singapore
- 18:25 – 19:00 **Panel Discussion**
Panelists: Stephen Harrison, MD
University of Oxford
San Antonio, Texas, USA

Quentin Anstee, BSc(Hons), MBBS, PhD
Newcastle University
Newcastle upon Tyne, United Kingdom

Dave E. Kleiner, MD, PhD
Head, Histopathology and Autopsy Pathology
Center for Cancer Research
National Cancer Institute
Bethesda, Maryland, USA

AGENDA

**** Mountain Standard Time ****

SATURDAY, MARCH 13, 2021

6:45 – 7:30

Breakfast – Exhibit Hall/Poster Viewing

SESSION 4: WHAT WOULD NASH TRIALS WITHOUT HISTOLOGY LOOK LIKE?

Moderators: Vlad Ratziu, MD – Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris (Paris, France),
Stephen Harrison, MD – University of Oxford (San Antonio, Texas, USA), and
Brent A. Tetri, MD – Saint Louis University School of Medicine (Saint Louis, Missouri, USA)

7:30 – 7:55

Serum Biomarkers and Prediction of Outcomes

Presenter: Mary Rinella, MD
Northwestern University Feinberg School of Medicine
Chicago, Illinois, USA

7:55 – 8:20

Precision Medicine: Incorporating Biomarkers into Clinical Trials

Presenter: David Pinato, MD, PhD
Imperial College
London, United Kingdom

8:20 – 8:40

Ready to Select Patients with Active NASH and Fibrosis without Biopsy?

Presenter: Philip Newsome, MD
University of Birmingham
Birmingham, United Kingdom

8:40 – 8:55

What Would NASH Trials without Biopsy Look Like?

Presenter: Vlad Ratziu, MD
Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris
Paris, France

8:55 – 9:20

Imaging Biomarkers and Prediction of Histologic Response and Fibrosis Change and Outcomes

Presenter: Rohit Loomba, MD, MHSc
University of California at San Diego
San Diego, California, USA

9:20 – 9:50

Panel Discussion

Panelists: Vlad Ratziu, MD
Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris
Paris, France

Stephen Harrison, MD
University of Oxford
San Antonio, Texas, USA

Suneil Hosmane, PhD
Global Head Diagnostics
Genfit
Cambridge, Massachusetts, USA

Céline Fournier, PhD
Chief Medical Officer
Echosens
Paris, France

Robert Myers
Senior Director, Liver Disease Therapeutic Area
Gilead Sciences
Foster City, California, USA

9:50 – 10:20

Break – Exhibit Hall/Poster Viewing

AGENDA

SESSION 5: SPECIAL POPULATIONS IN NASH TRIALS

Moderators: Celeste C. Thomas, MD, MS – University of Chicago (Chicago, Illinois, USA),
Arun Sanyal, MD – Virginia Commonwealth University (Richmond, Virginia, USA),
Philip Newsome, MD – University of Birmingham (Birmingham, United Kingdom),
Steven K. Grinspoon, MD – Harvard Medical School (Boston, Massachusetts, USA) and
Stephen Harrison, MD – University of Oxford (San Antonio, Texas, USA)

10:20 – 10:45 **NASH in HIV and Other Unique Populations: A Specific Unmet Need?**

Presenter: Giada Sebastiani, MD
McGill University Health Centre
Montreal, Canada

10:45 – 11:10 **The Elephant in the Room: NASH and Moderate Alcohol Consumption**

Presenter: Quentin Anstee, BSc(Hons), MBBS, PhD
Newcastle University
Newcastle upon Tyne, United Kingdom

MINI DEBATES: DIABETES DRUGS FOR NASH: NO NEED TO LOOK ELSEWHERE!

Moderator: Michael Charlton, MBBS, FRCP – University of Chicago (Chicago, Illinois, USA)

11:10 – 11:25 **Yes Indeed!**

Presenter: Sven Francque, MD, PhD
University of Antwerp
Edegem, Belgium

11:25 – 11:40 **Not So Fast!**

Presenter: Arun J. Sanyal, MD
Virginia Commonwealth University
Richmond, Virginia, USA

11:40 – 11:50 **Panel Discussion**

11:50 – 16:00 **A la Carte Roundtable Discussion Related to Drug Development**

SESSION 6: BASIC SCIENCE

Moderators: Scott Friedman, MD – Icahn School of Medicine at Mount Sinai (New York, New York, USA),
Arun Sanyal, MD – Virginia Commonwealth University (Richmond, Virginia, USA),
Manal Abdelmalek, MD, MPH – Duke University (Durham, North Carolina, USA), and
Naim Alkhouri, MD – Arizona Liver Health (Glendale, Arizona, USA)

16:00 – 16:25 **Preclinical Models: Lots of Information – Is Any of It Useable?**

Presenter: Brent A. Tetri, MD
Saint Louis University School of Medicine
Saint Louis, Missouri, USA

16:25 – 16:30 **Q&A**

16:30 – 16:55 **Microbiome in NASH: Implications of Pathophysiology and Therapy**

Presenter: Bernd Schnabl, MD
University of California at San Diego
San Diego, California, USA

16:55 – 17:00 **Q&A**

17:00 – 17:25 **Directly Targeting Novel Mechanisms for Fibrosis TGF-Beta and Integrins**

Presenter: Scott Friedman, MD
Icahn School of Medicine at Mount Sinai
New York, New York, USA

17:25 – 17:30 **Q&A**

17:30 – 17:55 **Advances in Genetics and Gene Silencing in NASH**

Presenter: Rohit Loomba, MD, MHSc
University of California at San Diego
San Diego, California, USA

AGENDA

17:55 – 18:00

Q&A

18:00 – 18:30

Break – Exhibit Hall/Poster Viewing

SESSION 7: NEW PHARMACOLOGICAL TARGETS

*Moderators: Vlad Ratzu, MD – Hôpital Pitié Salpêtrière, Institute of Cardiometabolism and Nutrition and University of Paris (Paris, France),
Michael Charlton, MBBS, FRCP – University of Chicago (Chicago, Illinois, USA), and
M. Scott Harris, MD – Chief Medical Officer – Altimune (Gaithersburg, Maryland, USA)*

18:30 – 18:45

DGAT2+ACC – Pfizer, Inc.

*Presenter: William Esler, PhD
Senior Director
Cambridge, Massachusetts, USA*

18:45 – 19:00

SSAO/VAP-1 – Terns Pharmaceuticals

*Presenter: Erin Quirk, MD
President and Chief Medical Officer
Foster City, California, USA*

19:00 – 19:15

TLR Signaling Inhibition With Mosedipimod – Enzychem

*Presenter: Michael Charlton, MBBS, FRCP
University of Chicago
Chicago, Illinois, USA*

19:15 – 19:30

CRV431 – Pancyclophilin Inhibitor – Hepion Pharmaceuticals, Inc

*Presenter: Robert T. Foster, PharmD, PhD
Chief Executive Officer
Edmonton, Canada*

19:30 – 19:45

GLP1/Glucagon Agonists – Altimune

*Presenter: M. Scott Harris, MD, MS, FACP, AGAF
Chief Medical Officer
Gaithersburg, Maryland, USA*

19:45 – 19:55

NASH-TAG 2021 Recap and Future

*Presenter: Stephen Harrison, MD
University of Oxford
San Antonio, Texas, USA*

19:55

Meeting Adjourn

2021 NASH-TAG SUPPORT OPPORTUNITIES AND IMPORTANT DEADLINES

SUPPORT OPPORTUNITIES

The NASH-TAG Conference offers different levels of sponsorship to support the needs of the more than 250 healthcare professionals who will attend the conference.

NASH-TAG CONFERENCE DATES

March 11-13, 2021

The Chateaux Deer Valley
7815 Royal Street East
Park City, Utah 84060
USA

IMPORTANT DEADLINES

Initial Agreement: Supporters showing interest must commit in writing by completing the "Support Opportunities" found on the last page of this prospectus.

Payment: If requested, invoices can be generated on receipt of the fully executed Letter of Agreement with payment due 60 days from the date of the signed Letter of Agreement. Please include a copy of the invoice and/or purchase order with payment.

Checks should be made payable to:
Focus Medical Communications (Tax ID 20-8216514)

Remit payment to:
Focus Medical Communications
Attn: NASH-TAG
7 Century Drive, Suite 104
Parsippany, NJ 07054

SPONSORSHIP OPPORTUNITIES

The NASH-TAG Conference has designed a comprehensive and multi-tiered corporate sponsorship program that provides benefits at every level. We are excited to announce a new annual corporate sponsorship package for the Diamond, Platinum, and Gold levels. These packages are designed for companies and organizations interested in supporting NASH-TAG on an annual basis. As a corporate sponsor, your company will be listed as the main contributor on the NASH-TAG website.

DIAMOND: \$100,000

At the NASH-TAG Conference:

- Eight (8) complementary conference registrations
- Executive board exchange: The opportunity for up to eight (8) people from your organization to meet live or virtually with the NASH-TAG course directors over lunch* to discuss anything related to your product and NASH/NAFLD
- A company-sponsored industry forum*
- Eight (8) invitations to the faculty dinner
- Networking Reception Sponsor
- 12-foot conference exhibit booth & a virtual exhibit booth for attendees that can't travel to the live program
- Two (2) promotional bag inserts in the conference bag
- Acknowledgment as a Diamond Sponsor on individual conference websites and all conference materials

** Lunch in-person meeting must be on either Friday or Saturday from 12:30 - 1:30PM. The virtual meeting can be either on Friday/ Saturday from 12:30 - 1:30PM, or arrangements can be made at a time and date post NASH-TAG. First come first served. Company responsible for food and beverages.*

** NASH-TAG Conference will supply the room and AV only. For the virtual meeting, NASH-TAG will provide the Zoom platform. Company responsible for food and beverages*

** Available times: Friday 1:30PM - 3:00PM | Saturday 1:30 PM - 3:00 PM*

PLATINUM: \$50,000

At the NASH-TAG Conference:

- Six (6) conference registrations
- Four (4) invitations to the faculty dinner
- Networking Reception Sponsor
- 12-foot conference exhibit booth & a virtual exhibit booth for attendees that can't travel to the live program
- Two (2) promotional bag inserts in the conference bag
- Acknowledgment as a Platinum Sponsor on individual conference websites and all conference materials

GOLD: \$25,000

At the NASH-TAG Conference:

- Three (3) conference registrations
- Two (2) invitations to the faculty dinner
- Networking Reception Sponsor
- 6-foot conference exhibit booth & a virtual exhibit booth for attendees that can't travel to the live program
- One (1) promotional bag insert in the conference bag
- Acknowledgment as a Gold Sponsor on individual conference websites and all conference materials

CONFERENCE SPONSOR: \$10,000

At the NASH-TAG Conference:

- 6-foot highly visible exhibit space & a virtual exhibit booth
- Acknowledgment as a Conference Sponsor on individual conference websites and all conference materials

To discuss conference support opportunities further, please contact:

Pablo Gabella

Sr. Director, Business Development

Focus Medical Communications

Tel: 714-869-2769

pgabella@focusmeded.com

2021 NASH-TAG EXHIBIT

SPONSOR INFORMATION FORM

TO SECURE YOUR SPONSORSHIP,
CLICK HERE
TO COMPLETE THE ONLINE FORM AND AGREEMENT

To further discuss conference support opportunities, please contact:

Pablo Gabella

Senior Director, Business Development
Focus Medical Communications

Tel: 714-890-2769

pgabella@focusmeded.com

Checks should be made payable to:

Focus Medical Communications
(Tax ID 20-8216514)

Remit payment to:

Focus Medical Communications

Attn: NASH-TAG

7 Century Drive, Suite 104

Parsippany, NJ 07054

EXHIBITOR REGISTRATION INSTRUCTIONS

Your exhibit space is contingent on receiving full payment. All additional requests (e.g., power source, internet access) will be handled between the exhibitor and the hotel. The costs will be directly charged to the exhibitor.

EXHIBIT SPACE SELECTION

The NASH-TAG conference planners will assign the exhibit location in the expo area. Please indicate on your registration form if there are any special circumstances regarding your display.

CANCELLATION POLICY

- A refund, less a handling fee of 10%, will be given for cancellations received in writing within 3 business days after the Sponsorship/Exhibitor's Agreement is completed using the online webform. After this date, no refunds will be granted unless the conference is cancelled altogether.
- If the conference is postponed and rescheduled within one year of the originally scheduled date, no refunds will be granted. However, the sponsorship/exhibitor fee shall be applied to the rescheduled conference.
- Should the conference be cancelled and does not take place within one year of the originally scheduled date, a full refund shall be granted.

LIABILITY

The Exhibitor agrees to defend, indemnify and hold harmless the conference venue Hotel, The NASH-TAG CONFERENCE and Focus Medical Communications, along with their employees, agents, representatives, and guests, from any third party claim, cause of action, liability, damage, cost or expense of any kind whatsoever arising out of or relating in any way to the Exhibitor's alleged intentional or negligent conduct during or in connection with its participation in the conference, including the reimbursement of all damages assessed and reasonable attorneys' fees and costs incurred.

INSURANCE FOR EXHIBIT ITEMS

The Exhibitor assumes all risk and financial responsibility for the loss or damage of its personal property during or related in any to the conference. The Exhibitor further acknowledges that it is responsible for insuring its personal property and that NASH-TAG CONFERENCE does not maintain any insurance coverage for that purpose. The EXHIBITOR forever releases and otherwise waives all claims against the conference venue Hotel, The NASH-TAG CONFERENCE and Focus Medical Communications, along with their employees, agents, representatives, and guests, arising out of or relating to the loss or damage of the Exhibitor's personal property.

Signature: _____ Date: _____

Print Name: _____



For more information, please visit:

WWW.NASH-TAG.ORG

Follow Us on Twitter!

@NashTagConf